Francesca Bergamo
About
Francesca Bergamo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Francesca Bergamo has authored 211 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 180 papers in Oncology, 83 papers in Pulmonary and Respiratory Medicine and 52 papers in Cancer Research. Recurrent topics in Francesca Bergamo's work include Colorectal Cancer Treatments and Studies (129 papers), Cancer Genomics and Diagnostics (43 papers) and Cancer Treatment and Pharmacology (41 papers). Francesca Bergamo is often cited by papers focused on Colorectal Cancer Treatments and Studies (129 papers), Cancer Genomics and Diagnostics (43 papers) and Cancer Treatment and Pharmacology (41 papers). Francesca Bergamo collaborates with scholars based in Italy, United States and Spain. Francesca Bergamo's co-authors include Sara Lonardi, Fotios Loupakis, Vittorina Zagonel, Marta Schirripa, Chiara Cremolini, Alfredo Falcone, Gianluca Masi, Lisa Salvatore, Matteo Fassan and Carlotta Antoniotti and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Cancer.
In The Last Decade
Francesca Bergamo
189 papers receiving 2.4k citations
Peers
Francesca Bergamo
Alessio Amatu Italy
Nobuyuki Mizunuma Japan
D. Fennelly Ireland
Pavlos Papakostas Greece
Ho-Kyung Chun South Korea
Allyson J. Ocean United States
M Francoual France
Frank A. Scappaticci United States
G. Deplanque France
B. Massidda Italy
Citations per year, relative to Francesca Bergamo Francesca Bergamo (= 1×)
peers
Alessio Amatu
Countries citing papers authored by Francesca Bergamo
Since
Specialization
Citations
This map shows the geographic impact of Francesca Bergamo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesca Bergamo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesca Bergamo more than expected).
Fields of papers citing papers by Francesca Bergamo
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Francesca Bergamo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesca Bergamo. The network helps show where Francesca Bergamo may publish in the future.
Co-authorship network of co-authors of Francesca Bergamo
This figure shows the co-authorship network connecting the top 25 collaborators of Francesca Bergamo. A scholar is included among the top collaborators of Francesca Bergamo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesca Bergamo. Francesca Bergamo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Moretto, Roberto, Daniele Rossini, Carlotta Antoniotti, et al.. (2025). The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies. European Journal of Cancer. 222. 115470–115470.
2.
Antoniotti, Carlotta, Federica Marmorino, Daniele Rossini, et al.. (2025). FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials. European Journal of Cancer. 228. 115713–115713.
3.
Angerilli, Valentina, Michele Paudice, Paola Fugazzola, et al.. (2025). Heterogeneity of predictive biomarker expression in gastric and esophago-gastric junction carcinoma with peritoneal dissemination. Gastric Cancer. 28(4). 569–578.
4.
Angerilli, Valentina, Rossana Intini, Francesca Bergamo, et al.. (2024). Detecting BRAF mutations in colorectal cancer in clinical practice: An Italian experts' position paper. Critical Reviews in Oncology/Hematology. 206. 104574–104574.
5.
Raimondi, A., Federica Palermo, Federica Morano, et al.. (2024). 498TiP Adjuvant trastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: The TRINITY trial. Annals of Oncology. 35. S198–S199.
6.
Conca, Veronica, Paola Vignali, Daniele Rossini, et al.. (2024). Negative hyperselection and mechanisms of acquired resistance to first-line chemotherapy plus anti-EGFR in patients (pts) with pMMR RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): A translational analysis of the TRIPLETE trial.. Journal of Clinical Oncology. 42(16_suppl). 3572–3572.
7.
Conca, Veronica, Roberto Moretto, Carlotta Antoniotti, et al.. (2024). Trifluridine/tipiracil plus capecitabine and bevacizumab as upfront treatment for metastatic colorectal cancer: Results of the phase 1 TriComB study.. Journal of Clinical Oncology. 42(16_suppl). 3558–3558.
8.
Fanotto, V., Daniele Rossini, Mariaelena Casagrande, et al.. (2023). Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies. Cancers. 15(22). 5451–5451.
9.
Scarpa, Marco, Giada Munari, Antonio Scapinello, et al.. (2023). Role of Immune Microenvironment in Pancreatic Ductal Adenocarcinoma: Could It Be Considered a Predictor of Prognosis?. Current Oncology. 30(6). 5515–5528.
10.
Gallois, Claire, Julien Taı̈eb, Sara Lonardi, et al.. (2023). Transcriptomic signatures of MSI-high metastatic colorectal cancer to predict efficacy of immune checkpoint inhibitors.. Journal of Clinical Oncology. 41(16_suppl). 3570–3570.
11.
Fucà, Giovanni, Alessandra Raimondi, Michele Prisciandaro, et al.. (2022). Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study. The Oncologist. 27(1). e29–e36.
12.
Bergamo, Francesca, Eleonora Bergo, Francesca Daniel, et al.. (2022). The oncological multidimensional prognostic index is a promising decision-making tool: A real-world analysis in older patients with metastatic colorectal cancer. European Journal of Cancer. 177. 112–119.
13.
Zaniboni, Alberto, Carlo Barone, Maria Banzi, et al.. (2021). Italian Results of the PRECONNECT Study: Safety and Efficacy of Trifluridine/tipiracil in Metastatic Colorectal Cancer. Future Oncology. 17(18). 2315–2324.
14.
Bergamo, Francesca, Francesca Daniel, Cosimo Rasola, et al.. (2021). A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study. Cancers. 13(20). 5128–5128.
15.
Sartore‐Bianchi, Andrea, Federica Tosi, Francesca Bergamo, et al.. (2020). 507P Central nervous system recurrence in HER2-positive metastatic colorectal cancer. Annals of Oncology. 31. S455–S455.
16.
Schirripa, Marta, Beatrice Borelli, Romina D’Aurizio, et al.. (2019). Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib. The Pharmacogenomics Journal. 19(5). 455–464.
17.
Schirripa, Marta, Giuseppe Pasqualetti, Riccardo Giampieri, et al.. (2018). Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study. Clinical Colorectal Cancer. 17(3). e601–e615.
18.
Ferrarese, Alberto, Francesca Bergamo, Fiorella Calabrese, et al.. (2017). An untreatable dyspnoea: more defendants under investigation. Internal and Emergency Medicine. 12(2). 199–205.
19.
Catalano, Vincenzo, Francesca Bergamo, Chiara Cremolini, et al.. (2017). Does bevacizumab plus chemotherapy matter in metastatic colorectal cancer patients with mucinous histology? A multicenter, retrospective analysis on 685 patients. Annals of Oncology. 28. vi3–vi3.
20.
Salvatore, Lisa, Fotios Loupakis, Chiara Cremolini, et al.. (2012). Folfoxiri plus Bevacizumab as first-line treatment of BRAF mutant metastatic colorectal cancer patients.. Annals of Oncology. 23.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Alessio Amatu Breakdown of academic impact, for papers by Nobuyuki Mizunuma Breakdown of academic impact, for papers by D. Fennelly Breakdown of academic impact, for papers by Pavlos Papakostas Breakdown of academic impact, for papers by Ho-Kyung Chun Breakdown of academic impact, for papers by Allyson J. Ocean Breakdown of academic impact, for papers by M Francoual Breakdown of academic impact, for papers by Frank A. Scappaticci Breakdown of academic impact, for papers by G. Deplanque Breakdown of academic impact, for papers by B. Massidda